Overcoming drug resistance with EAI-432, an allosteric EGFR inhibitor for non-small cell lung cancer
Researchers at Dana-Farber Cancer Institute have developed a promising new drug candidate, EAI-432, to treat non-small cell lung cancers (NSCLC)driven by mutations in the EGFR gene, particularly the L858R mutation which is ...